rotation.to
Following this device: dark.
Free account
rotation.to
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

Rafael Holdings, Inc.

RFL · NYSE

Health CareBiotechnologyNot moving yet

RFL stood above a rising 150-day average in 17 of the last 52 weekly readings, and has been out of that trend for the last 3 weeks. It is 29.1% below that average now. Biotechnology: 18% of its 561 stocks in an uptrend (−14 points in four weeks); Health Care: 28% (−9 points in four weeks).

Statistics

Rotation
Not moving yet
Weeks in an uptrend
out for 3
Industry in uptrend
18% -14 in 4 wk
Insider buys, 12 months
$0
Insider sales, 12 months
$0
Officials’ trades on record
0
Institutions holding
41 (+6)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 17 of 52 weeks.

21 Apr – 20 Oct
18%28%39%Apr 26Jun 26Jul 26Sep 26Oct 26

Biotechnology: Few of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.

Money in and out

1 Nov 2024 – 1 Oct 2026
$0$16.1MNov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars.

Congress and officials

No member of Congress or official has disclosed a trade in it.

Insiders

Buy orders, 12 months0
Sale orders, 12 months0
Buyers · sellers0 · 0

No open-market buy or sale by its insiders on record.

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders41+6 on the quarter
New · exited11 · 5
Reported value$12.3M

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

ManagerSharesChange
VANGUARD CAPITAL MANAGEMENT LLCnew · filed 13 Aug 20261,365,997$4.5M+1,365,997
GEODE CAPITAL MANAGEMENT, LLCreduced · filed 12 Aug 2026429,879$1.4M-12,525−2.8%
BlackRock, Inc.added · filed 7 Aug 2026390,068$1.3M+24,450+6.7%
DIMENSIONAL FUND ADVISORS LPunchanged · filed 11 Aug 2026278,910$915K00.0%
VANGUARD FIDUCIARY TRUST COnew · filed 13 Aug 2026206,521$677K+206,521
IEQ CAPITAL, LLCreduced · filed 11 Aug 2026164,963$541K-24,997−13.2%
STATE STREET CORPadded · filed 7 Aug 2026157,270$516K+95,100+153.0%
JANE STREET GROUP, LLCadded · filed 14 Aug 2026112,720$370K+67,675+150.2%
WELLS FARGO & COMPANYadded · filed 14 Aug 2026103,590$340K+239+0.2%
NORTHERN TRUST CORPadded · filed 13 Aug 202688,602$291K+4,588+5.5%
31 Mar 2023 – 30 Jun 2026
303743Mar 23Dec 23Dec 24Sep 25Jun 26

Everyone who traded it

David Polinsky Company insiderChief Financial Officer · last 21 Sep 20260 · 0
Howard S. Jonas Company insiderExec Chairman, CEO & President · last 29 Jul 20263 · 3
Alan Grayson Company insiderDirector · last 28 Jan 20260 · 0
Mark N. Stein Company insiderDirector · last 28 Jan 20260 · 0
Markus Sieger Company insiderDirector · last 28 Jan 20260 · 0
Michael J. Weiss Company insiderDirector · last 28 Jan 20260 · 0
Joshua M. Fine Company insiderChief Operating Officer · last 3 Sep 20250 · 0
William Conkling Company insiderChief Executive Officer · last 25 Mar 20250 · 0
John Goldberg Company insiderCHIEF MEDICAL OFFICER · last 13 Jan 20250 · 0
Stephen M. Greenberg Company insiderDirector · last 6 Jan 20250 · 0
Mark Anthony McCamish Company insiderDirector · last 5 Jan 20240 · 0
Boris C. Pasche Company insiderDirector · last 5 Jan 20230 · 0

Same industry

MRNA ModernaLeading+167%
ENTX Entera BioLeading+52%
XNCR XencorLeading+41%

Distance from each stock’s own 150-day average.

Government contracts

No federal award is tied to it.

From its SEC filings

Profit per saleFY 2024 · to 31 Jul 202475.8%
Return on capital employedFY 2025 · to 31 Jul 2025-28.4%
Interest coverFY 2025 · to 31 Jul 2025-44.31×
Research spendFY 2025 · to 31 Jul 202525.3%
Cash and equivalentsFY 2025 · to 31 Jul 2025$52.8M
Free cash flowFY 2025 · to 31 Jul 2025−$18.9M

Analyst forecasts

No analyst forecasts yet.